EL7.AI
StocksMedium•9 November 2026•
3 min read

Rani Therapeutics Posts Net Loss of $8.806 Million as Cash Balance Declines

Key Facts

1Net loss was $8.806 million in the third quarter of 2026, compared with $7.914 million a year earlier.
2Cash, cash equivalents and marketable securities totaled $45.3 million on September 30, and the company expects them to fund operations through at least the end of 2027.
3Research and development expenses rose to $6.021 million from $3.221 million, and general and administrative expenses rose to $4.909 million from $4.036 million year over year.
4Net loss for the first nine months declined to $25.242 million from $31.876 million.
5The company said systemic exposure to RT-114 exceeded 150% compared with a 12 mg subcutaneous dose of PG-102.

Rani Therapeutics reported on November 9 financial results for the third quarter ended September 30, 2026, posting a net loss of $8.806 million, compared with $7.914 million in the same period a year earlier. The company said in a statement that it had $45.3 million in cash, cash equivalents and marketable securities at the end of September. It added that it expected these resources to fund operations through at least the end of 2027. The results put the quarterly loss and available resources at the center of the company's financial update. They also showed higher research and development and general and administrative expenses compared with the third quarter of 2025.

Research and development expenses totaled $6.021 million in the third quarter, compared with $3.221 million a year earlier. General and administrative expenses rose to $4.909 million from $4.036 million in the same period of 2025. By contrast, net loss for the first nine months of the year narrowed to $25.242 million, compared with $31.876 million in the first nine months of 2025. The comparison shows that the quarterly net loss widened year over year, while the total loss for the nine-month period declined. This did not change the company's statement that its cash and marketable securities totaled $45.3 million on September 30.

Cash and marketable securities stood at $53.4 million on June 30, 2026, according to the company's second-quarter update, compared with $43.4 million on March 31. The company said at the time that its cash resources were expected to fund operations through at least 2027. In its third-quarter results, the company put the balance at $45.3 million at the end of September and said it expected funding to continue through at least the end of 2027. In July, Rani reported that systemic exposure to RT-114 exceeded 150% compared with a matched 12 mg dose of subcutaneous PG-102. The company said no serious adverse events were recorded in either arm of the Phase 1a study, and no adverse events were attributed to the capsule.

In its corporate update, Rani said it announced in October that the RaniPill Capsule technology had been accepted into the U.S. Food and Drug Administration's Emerging Technology Program. The company explained that participation in the program does not mean the agency has approved the platform or any drug candidate. This regulatory development comes alongside the RT-114 data the company reported in July as part of its program updates. The third-quarter results remain associated with a higher quarterly net loss than a year earlier and a cash balance below its level at the end of June. The funding horizon the company announced on November 9 extends, according to its forecast, through at least the end of 2027.

Open on chart